These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 15004073)

  • 1. Laboratory detection of Haemophilus influenzae with decreased susceptibility to nalidixic acid, ciprofloxacin, levofloxacin, and moxifloxacin due to GyrA and ParC mutations.
    Pérez-Vázquez M; Román F; Aracil B; Cantón R; Campos J
    J Clin Microbiol; 2004 Mar; 42(3):1185-91. PubMed ID: 15004073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activities of garenoxacin (BMS-284756) against Haemophilus influenzae isolates with different fluoroquinolone susceptibilities.
    Pérez-Vázquez M; Román F; Aracil B; Cantón R; Campos J
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3539-41. PubMed ID: 14576114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular characterization of fluoroquinolone resistance in nontypeable Haemophilus influenzae clinical isolates.
    Puig C; Tirado-Vélez JM; Calatayud L; Tubau F; Garmendia J; Ardanuy C; Marti S; de la Campa AG; Liñares J
    Antimicrob Agents Chemother; 2015 Jan; 59(1):461-6. PubMed ID: 25385097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quinolone-resistant Haemophilus influenzae: determination of mutant selection window for ciprofloxacin, garenoxacin, levofloxacin, and moxifloxacin.
    Li X; Mariano N; Rahal JJ; Urban CM; Drlica K
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4460-2. PubMed ID: 15504883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hotspots sequences of gyrA, gyrB, parC, and parE genes encoded for fluoroquinolones resistance from local Salmonella Typhi strains in Jakarta.
    Nathania I; Nainggolan IM; Yasmon A; Nusatia ACM; Tjoa E; Gunardi WD; Moehario LH
    BMC Microbiol; 2022 Oct; 22(1):250. PubMed ID: 36253712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Nishino Y; Ishihara S; Kawada Y
    J Antimicrob Chemother; 1997 Oct; 40(4):543-9. PubMed ID: 9372424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoroquinolone resistance in Haemophilus influenzae from nursing home residents in Taiwan: correlation of MICs and mutations in QRDRs.
    Chang CM; Shih HI; Wu CJ; Lauderdale TL; Lee NY; Lee CC; Chen YC; Huang CC; Ko WC
    J Appl Microbiol; 2020 Jun; 128(6):1624-1633. PubMed ID: 31951091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
    J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.
    Allen GP; Kaatz GW; Rybak MJ
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2606-14. PubMed ID: 12878526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GyrA and/or ParC alterations of Haemophilus influenzae strains isolated from the urethra of men with acute urethritis.
    Kondo H; Ito S; Hatazaki K; Horie K; Nakane K; Mizutani K; Tsuchiya T; Yasuda M; Yokoi S; Nakano M; Deguchi T
    J Infect Chemother; 2018 Mar; 24(3):232-235. PubMed ID: 29138021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of gemifloxacin against clinical isolates of Neisseria gonorrhoeae with and without mutations in the gyrA gene.
    Ruiz J; Marco F; Sierra JM; Aguilar L; Garcia-Mendez E; Mensa J; Jiménez De Anta MT; Vila J
    Int J Antimicrob Agents; 2003 Jul; 22(1):73-6. PubMed ID: 12842332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.
    Brueggemann AB; Coffman SL; Rhomberg P; Huynh H; Almer L; Nilius A; Flamm R; Doern GV
    Antimicrob Agents Chemother; 2002 Mar; 46(3):680-8. PubMed ID: 11850248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.
    Jorgensen JH; Weigel LM; Ferraro MJ; Swenson JM; Tenover FC
    Antimicrob Agents Chemother; 1999 Feb; 43(2):329-34. PubMed ID: 9925527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones.
    Yamada M; Yoshida J; Hatou S; Yoshida T; Minagawa Y
    Br J Ophthalmol; 2008 Jun; 92(6):848-51. PubMed ID: 18460536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Earlier generation quinolones can be useful in identifying Haemophilus influenzae strains with low susceptibility to quinolone isolated from paediatric patients.
    Tanaka E; Wajima T; Noguchi N
    J Med Microbiol; 2019 Aug; 68(8):1227-1232. PubMed ID: 31215858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC.
    Shultz TR; Tapsall JW; White PA
    Antimicrob Agents Chemother; 2001 Mar; 45(3):734-8. PubMed ID: 11181352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uncommon occurrence of fluoroquinolone resistance-associated alterations in GyrA and ParC in clinical strains of Chlamydia trachomatis.
    Yokoi S; Yasuda M; Ito S; Takahashi Y; Ishihara S; Deguchi T; Maeda S; Kubota Y; Tamaki M; Fukushi H
    J Infect Chemother; 2004 Oct; 10(5):262-7. PubMed ID: 16163459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in topoisomerase genes of fluoroquinolone-resistant salmonellae in Hong Kong.
    Ling JM; Chan EW; Lam AW; Cheng AF
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3567-73. PubMed ID: 14576119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a Pefloxacin Disk Diffusion Method for Detection of Fluoroquinolone-Resistant Salmonella enterica.
    Skov R; Matuschek E; Sjölund-Karlsson M; Åhman J; Petersen A; Stegger M; Torpdahl M; Kahlmeter G
    J Clin Microbiol; 2015 Nov; 53(11):3411-7. PubMed ID: 26292292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.
    Biedenbach DJ; Jones RN; Pfaller MA;
    Diagn Microbiol Infect Dis; 2001 Apr; 39(4):245-50. PubMed ID: 11404068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.